Home›Clinical trials›North Carolina

GLP-1 clinical trials in North Carolina: 30 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

30 GLP-1 clinical trials are recruiting at 66 sites in 19 cities across North Carolina. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in North Carolina

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in North Carolina

    • Atrium Health Family Medicine Research Department, Charlotte. 704-304-7176
    • Duke University Hospital, Durham. 919-668-9049

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    2 sites in North Carolina

    • Revival Research Institute, LLC, Cary
    • Onsite Clinical Solutions - Huntersville, Huntersville. 800-785-3150

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    1 site in North Carolina

    • Onsite Clinical Solutions, LLC - Brenner Ave, Salisbury. 800-785-3150

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  1. Tirzepatide in Idiopathic Intracranial Hypertension Trial

    Phase 4. Duke University plans to enroll 60 participants.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with idiopathic intracranial hypertension (IIH).

    Who can join. Adults 18 to 60, have idiopathic intracranial hypertension (IIH), BMI 30+.

    1 site in North Carolina

    NCT07191873 on ClinicalTrials.gov. See whether you qualify.

  2. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    6 sites in North Carolina
    • PharmQuest Life Sciences LLC, Greensboro
    • Physician's East Endocrinology, Greenville
    • Carteret Medical Group, Morehead City
    • Centricity Rsrch MHCity Multi, Morehead City
    • Piedmont Healthcare/Research, Statesville
    • Accellacare Wilmington, Wilmington

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in North Carolina

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    5 sites in North Carolina
    • Research Site, Durham
    • Research Site, Morehead City
    • Research Site, Raleigh
    • Research Site, Statesville
    • Research Site, Wilmington

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  5. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    3 sites in North Carolina

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    3 sites in North Carolina

    • UNC Children's Hospital, Chapel Hill
    • Duke Children's Primary Care, Durham
    • Lucas Research, Inc, Morehead City. 252-222-5700

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in North Carolina

    • Duke University - Main Hospital and Clinics, Durham
    • Monroe Biomedical Research, Monroe. 704-283-7359
    • Carteret Medical Group, Morehead City. 252-499-8623

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

The other 20 studies recruiting in North Carolina

  1. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    3 sites in North Carolina

    • Centricity Research Morehead City Specialty, Morehead City
    • Accellacare of Raleigh, Raleigh
    • Accellacare Research of Wilmington, Wilmington

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  2. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in North Carolina

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  3. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in North Carolina

    • Asheville VA Medical Center, Asheville, NC, Asheville. 8282987911
    • Durham VA Medical Center, Durham, NC, Durham

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  4. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in North Carolina

    • Kailera Clinical Site, Morehead City
    • Kailera Clinical Site, Morrisville

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  5. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 285 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    2 sites in North Carolina

    • PharmQuest, Greensboro
    • KDCILM, LLC & Accellacare US, Inc., Wilmington

    NCT07745504 on ClinicalTrials.gov. See whether you qualify.

  6. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in North Carolina

    • Lucas Research, Inc., Morehead City

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  7. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in North Carolina

    • Coastal Research Institute - Fayetteville, Fayetteville

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  8. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in North Carolina

    • Coastal Research Institute - Fayetteville, Fayetteville

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  9. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in North Carolina

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  10. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in North Carolina

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  11. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    2 sites in North Carolina

    • Carteret Medical Group, Morehead City
    • Brookview Hills Research Associates, LLC, Winston-Salem

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  12. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    2 sites in North Carolina

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  13. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in North Carolina

    • PharmQuest, Greensboro
    • Piedmont Healthcare Statesville, Statesville

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  14. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in North Carolina

    • PharmQuest, Greensboro
    • KDCILM, LLC & Accellacare US, Inc., Wilmington

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  15. Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. University of Colorado, Denver plans to enroll 200 participants.

    A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in North Carolina

    • University of North Carolina, School of Medicine, Chapel Hill. 919-908-0010

    NCT06975111 on ClinicalTrials.gov. See whether you qualify.

  16. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in North Carolina

    • KDCILM, LLC & Accellacare US, Inc., Wilmington

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  17. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Novo Nordisk A/S plans to enroll 114 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in North Carolina

    • Monroe Biomedical Research, LLC, Monroe
    • Accellacare, Wilmington

    NCT07607587 on ClinicalTrials.gov. See whether you qualify.

  18. Tirzepatide in Obesity-Driven Endometrial Cancer

    Phase 1. UNC Lineberger Comprehensive Cancer Center plans to enroll 20 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with endometrial cancer lose weight.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 30+.

    1 site in North Carolina

    • Lineberger Comprehensive Cancer Center, Chapel Hill. 919-966-5996

    NCT07065552 on ClinicalTrials.gov. See whether you qualify.

  19. Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance

    Phase 1. David D'Alessio, M.D plans to enroll 30 participants.

    A study in people with diabetes.

    Who can join. Adults 18 to 60, have diabetes.

    1 site in North Carolina

    NCT07224334 on ClinicalTrials.gov. See whether you qualify.

  20. MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

    Dr. Christopher McGowan plans to enroll 20 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 21 to 65, have obesity, BMI 30+.

    1 site in North Carolina

    NCT06734312 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.